GlassScriptPhysician profile
Brent Wyatt Hinkle
NPI 1447434097
$12,250.45
in general payments reported to CMS, 2019-2025
47 companies · $2,536 in 2025
The $2,536 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,254 · 2020: $806 · 2021: $1,209 · 2022: $1,171 · 2023: $2,064 · 2024: $2,210 · 2025: $2,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,810.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,793.18 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,467.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,262.10 | 2019-2025 | Farxiga, Airsupra, Bevespi Aerosphere |
| Lilly USA, LLC | $1,113.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $735.46 | 2021-2025 | |
| Amgen INC. | $673.05 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $587.97 | 2019-2025 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $584.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $482.28 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $330.84 | 2019-2023 | Belsomra, Steglatro, Lagevrio |
| Otsuka America Pharmaceutical, INC. | $286.84 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $269.62 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $245.14 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $190.36 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $180.08 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Hinkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.